Verrica Pharmaceuticals - VRCA Stock Forecast, Price & News

Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and which is in Phase II clinical trial for treating common warts. It is also developing cantharidin-based product candidate, VP-103 for treating plantar warts. The company has a license and collaboration agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatological oncology indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.

Analyst Upgrades and Downgrades

VRCA has been the subject of a number of analyst reports. HC Wainwright reaffirmed a "buy" rating and set a $12.00 price objective on shares of Verrica Pharmaceuticals in a research note on Wednesday, June 29th. Royal Bank of Canada lowered shares of Verrica Pharmaceuticals from an "outperform" rating to a "sector perform" rating and reduced their price objective for the company from $16.00 to $4.00 in a research note on Wednesday, May 25th. Finally, Needham & Company LLC lowered shares of Verrica Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Wednesday, May 25th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $14.80.

Verrica Pharmaceuticals Stock Performance

Shares of NASDAQ:VRCA traded up $0.18 during mid-day trading on Thursday, reaching $3.63. The company had a trading volume of 146,389 shares, compared to its average volume of 278,128. The stock has a fifty day moving average of $2.76 and a two-hundred day moving average of $5.67. The company has a market capitalization of $99.89 million, a price-to-earnings ratio of -2.33 and a beta of 2.16. Verrica Pharmaceuticals has a 12-month low of $1.77 and a 12-month high of $14.79.

Verrica Pharmaceuticals (NASDAQ:VRCA - Get Rating) last posted its quarterly earnings results on Monday, May 9th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.59) by $0.29. The company had revenue of $0.43 million during the quarter. Sell-side analysts forecast that Verrica Pharmaceuticals will post -1.13 earnings per share for the current fiscal year.

Insider Transactions at Verrica Pharmaceuticals

In related news, CEO Ted White purchased 23,809 shares of Verrica Pharmaceuticals stock in a transaction dated Tuesday, July 5th. The stock was acquired at an average cost of $2.10 per share, with a total value of $49,998.90. Following the completion of the transaction, the chief executive officer now directly owns 29,466 shares of the company's stock, valued at $61,878.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, CEO Ted White acquired 23,809 shares of the company's stock in a transaction that occurred on Tuesday, July 5th. The shares were purchased at an average price of $2.10 per share, for a total transaction of $49,998.90. Following the completion of the acquisition, the chief executive officer now owns 29,466 shares of the company's stock, valued at approximately $61,878.60. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Perceptive Advisors Llc acquired 1,428,571 shares of the company's stock in a transaction that occurred on Tuesday, July 5th. The stock was purchased at an average price of $2.10 per share, for a total transaction of $2,999,999.10. Following the acquisition, the insider now directly owns 5,038,983 shares of the company's stock, valued at approximately $10,581,864.30. The disclosure for this purchase can be found here. Insiders purchased 1,703,689 shares of company stock valued at $3,587,497 over the last three months. 43.50% of the stock is owned by corporate insiders.